Background Implantable cardioverter-defibrillators (ICDs) are implanted with the intention to
prolong life in selected patients with inherited arrhythmia syndromes, but ICD implantation is …

Management strategies for ventricular arrhythmias are guided by the risk of sudden death
and severity of symptoms. Patients with a substantial risk of sudden death usually need an …

Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Background The implantable cardioverter–defibrillator (ICD) is highly effective in reducing
mortality among patients at risk for fatal arrhythmias, but inappropriate ICD activations are …

Aims To report 5-year outcomes of EFFORTLESS registry patients with early generation
subcutaneous implantable cardioverter-defibrillator (S-ICD) devices. Methods and results …

Aims The ECOST trial examined prospectively the long-term safety and effectiveness of
home monitoring (HM) of implantable cardioverter defibrillators (ICD). Methods and results …

It is known that myocardial ischaemia and infarction leads to severe metabolic and
electrophysiological changes that induce silent or symptomatic life-threatening arrhythmias …

The global burden caused by cardiovascular disease is substantial, with heart disease
representing the most common cause of death around the world. There remains a need to …

Endpoint selection is a critically important step in clinical trial design. It poses major
challenges for investigators, regulators, and study sponsors, and it also has important …